Blood Metabolite Scores Predict Age-Related Macular Degeneration Risk in Large Study

Age-related macular degeneration (AMD) affects 196 million people worldwide and represents a leading cause of blindness, yet early detection remains challenging. This large-scale prospective study demonstrates that blood-based metabolic vulnerability scores can effectively predict AMD development years before clinical diagnosis.

Researchers followed 265,000 UK Biobank participants for a median of 13.66 years, analyzing blood metabolites measured by nuclear magnetic resonance spectroscopy. They evaluated two metabolic indices: the Metabolic Vulnerability Index (MVX), derived from six inflammation and malnutrition markers, and the MetaboHealth score, based on 14 biomarkers reflecting biological aging.

Both scores showed strong dose-dependent associations with AMD risk. Participants in the highest quintile of MVX had a 17% increased risk (HR 1.17), while those with the highest MetaboHealth scores faced a 32% increased risk (HR 1.32). The associations were particularly pronounced in individuals with existing cardiovascular disease, diabetes, or other comorbidities. Genetic analysis revealed that people with both high genetic risk and high metabolic vulnerability scores had the greatest AMD risk—up to 3.14-fold higher than those with low scores.

Crucially, the metabolic scores correlated with structural retinal changes detectable by optical coherence tomography, including thinning of the photoreceptor segment layer—an early AMD hallmark. This provides biological validation that the blood biomarkers reflect actual disease processes in the eye.

These findings suggest that routine blood tests could identify high-risk individuals years before AMD symptoms appear, enabling targeted prevention strategies. The metabolic indices capture systemic processes like inflammation and metabolic dysfunction that contribute to AMD development, offering insights into disease mechanisms beyond genetic predisposition alone.